THERAPY DOSSIER · th-7cb59cbebb87

Growth hormone and zinc sulfate, alone and in combination

Hormone · Recombinant human growth hormone; growth hormone receptor agonist (ChEMBL MoA, direct interaction, disease efficacy true). Composite therapy: only the growth hormone component was resolved; zinc sulfate was not resolved separately in this run.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Recombinant human growth hormone; growth hormone receptor agonist (ChEMBL MoA, direct interaction, disease efficacy true). Composite therapy: only the growth hormone component was resolved; zinc sulfate was not resolved separately in this run.
Target: CHEMBL1976 (growth hormone receptor)
Injury models: Radiation · Other · Burn · Wound
Reported indication: Not recorded
First approval: 1976
Development stage: Not recorded
ChEMBL record: CHEMBL1201621 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Growth hormone; Human growth hormone; Somatotropin; Genotropin; Norditropin; Humatrope; Nutropin; Omnitrope; Saizen; Serostim; Zomacton
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01697644 ↗PHASE4completed

Growth Hormone Treatment of Children After Intrauterine Growth Retardation

Foetal Growth Problem · Small for Gestational Age

Enrolment: 75 · Results not recorded

NCT02185326 ↗PHASE4completed

Growth Hormone Co-treatment With the Microflare Stimulation Protocol in IVF/ICSI, Can it be a New Hope for Poor Responders?

Female Infertility Due to Diminished Ovarian Reserve

Enrolment: 145 · Results not recorded

NCT00990340 ↗PHASE4completed

Study to Compare Injection Anxiety Before Tev-Tropin Administration: Needle-syringe vs Needle-free Injection in Paediatric Human Growth Hormone Deficiency

Growth Hormone Deficiency

Enrolment: 52 · Results not recorded

Preclinical evidence 11

2 studies reported at therapy level; 11 evidence entries itemised.

PMID 28168533 ↗2017Reported benefit

Zinc Sulfate and/or Growth Hormone Administration for the Prevention of Radiation-Induced Dermatitis: a Placebo-Controlled Rat Model Study

RatRadiationSprague-DawleyMaleGrowth hormone subcutaneous; zinc oralGrowth hormone 0.01 IU per kg per day; zinc 5 mg per kg per…

Model: Radiation-induced skin injury produced by a single 30 Gy dose of gamma irradiation to the right hind legs

Irradiation produced dermatitis relative to non-irradiated controls (P<0.05). Radiodermatitis severity was significantly lower in the growth hormone, zinc and combined groups than in the irradiation only group (P<0.05), and dermatitis appeared earlier in the irradiation only group (P<0.05). Both ag…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

PMID 23636184 ↗2013Reported harm

Human growth hormone may be detrimental when used to accelerate recovery from acute tendon-bone interface injuries.

RatOtherSprague-Dawleyn = 72 rats in protocol 1 and 24 rats in protocol 2SubcutaneousProtocol 1: 0.1, 1, 2, 5 and 10 mg/kg/day. Protocol 2: 5 mg…Protocol 1 postoperative only; protocol 2 from seven days preoperatively until…

Model: Surgical repair of acute rotator cuff (tendon-to-bone) injury

Postoperative human growth hormone for fourteen days produced no significant biomechanical difference from placebo, while the longer twice-daily 5 mg/kg regimen gave lower ultimate force to failure (21.1 versus 26.3 N, p = 0.035) and more frequent failure through bone.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

PMID 16503890 ↗2006